Back to Search
Start Over
Refractory/Resistant Cytomegalovirus Infection in Transplant Recipients: An Update.
- Source :
-
Viruses [Viruses] 2024 Jul 05; Vol. 16 (7). Date of Electronic Publication: 2024 Jul 05. - Publication Year :
- 2024
-
Abstract
- Despite the significant progress made, CMV infection is one of the most frequent infectious complications in transplant recipients. CMV infections that become refractory or resistant (R/R) to the available antiviral drugs constitute a clinical challenge and are associated with increased morbidity and mortality. Novel anti-CMV therapies have been recently developed and introduced in clinical practice, which may improve the treatment of these infections. In this review, we summarize the treatment options for R/R CMV infections in adult hematopoietic cell transplant and solid organ transplant recipients, with a special focus on newly available antiviral agents with anti-CMV activity, including maribavir and letermovir.
- Subjects :
- Humans
Hematopoietic Stem Cell Transplantation adverse effects
Organ Transplantation adverse effects
Acetates
Dichlororibofuranosylbenzimidazole analogs & derivatives
Quinazolines
Cytomegalovirus Infections drug therapy
Cytomegalovirus Infections virology
Cytomegalovirus Infections etiology
Antiviral Agents therapeutic use
Transplant Recipients
Drug Resistance, Viral
Cytomegalovirus drug effects
Cytomegalovirus physiology
Subjects
Details
- Language :
- English
- ISSN :
- 1999-4915
- Volume :
- 16
- Issue :
- 7
- Database :
- MEDLINE
- Journal :
- Viruses
- Publication Type :
- Academic Journal
- Accession number :
- 39066247
- Full Text :
- https://doi.org/10.3390/v16071085